text: <unk>  is an aromatase inhibitor that is FDA approved for the treatment of adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer, advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.   Common adverse reactions include hot flashes, asthenia, arthritis, pain, arthralgia, pharyngitis, hypertension, depression, nausea and vomiting, rash, osteoporosis, fractures, back pain, insomnia, headache, peripheral edema and lymphedema.
option_0: Anastrozole
option_1: Tamoxifen
option_2: Letrozole
option_3: Goserelin
option_4: Lasofoxifene
option_5: Exemestane
option_6: Ormeloxifene
option_7: Gestrinone